IL-17 Inhibitor Brand Names
The FDA-approved IL-17 inhibitors have the following brand names: Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab). 1, 2
Available IL-17 Inhibitors
Secukinumab (Cosentyx)
- Brand name: Cosentyx 1
- Available as subcutaneous injection (300 mg/2 mL, 150 mg/mL, 75 mg/0.5 mL) and intravenous formulation (125 mg/5 mL) 1
- FDA-approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis, and hidradenitis suppurativa 3
- Directly inhibits IL-17A 4, 5
Ixekizumab (Taltz)
- Brand name: Taltz 6
- FDA-approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis 3
- Directly inhibits IL-17A 4, 5
- Demonstrates 89% PASI 75 response at 12 weeks 6
Brodalumab (Siliq)
- Brand name: Siliq (manufactured by Bausch Health) 7, 2
- FDA-approved for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond or lost response to other systemic therapies 2
- Inhibits IL-17 receptor A, blocking IL-17A, IL-17F, IL-17A/F, and IL-17E (IL-25) 7, 4
- Requires prescribing through SILIQ REMS program due to boxed warning for suicidal ideation and completed suicides 7
Mechanism Distinctions
- Secukinumab and ixekizumab: Direct IL-17A inhibitors 4, 5
- Brodalumab: IL-17 receptor A antagonist with broader blockade of IL-17 family members 7, 5